Vancomycin
Brand Names: Tyzavan, Vancocin HCl
Methodology & AI Transparency ⓘ
Vancomycin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage tyzavan: is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: Septicemia ( 1.1 ) Infective Endocarditis ( 1.2 ) Skin and Skin Structure Infections ( 1.3 ) Bone Infections ( 1.4 ) Lower Respiratory Tract Infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYZAVAN and other antibacterial drugs, TYZAVAN should be used only to treat or prevent infections that are proven or strongly.
- 2 Real-world patient consensus: Zero-PHI community consensus: 90% favorable across 12 logged regimens (Tyzavan, Vancocin HCl).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $22.25 wholesale mail-order against $54.51 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Vancomycin include diarrhea (10%), nausea (8.4%), headache (6.6%).
Ask our AI Specialists anything about Vancomycin
Vancomycin Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage tyzavan: is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: Septicemia ( 1.1 ) Infective Endocarditis ( 1.2 ) Skin and Skin Structure Infections ( 1.3 ) Bone Infections ( 1.4 ) Lower Respiratory Tract Infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYZAVAN and other antibacterial drugs, TYZAVAN should be used only to treat or prevent infections that are proven or strongly.
12.1 Mechanism of Action Vancomycin is an antibacterial drug . Biochemical activity of Vancomycin (NDC 0143-9466) reflects glycopeptide antibacterial receptor or enzymatic engagement paired with $0.3416/unit CMS NADAC reference benchmarks.
With Mean elimination half-life of 4 to 15 hours across adult Vancomycin dosing residence kinetics and Complete (~100%) parenteral systemic delivery for Vancomycin (750 mg/150mL Injection, Solution) bioavailability, Vancomycin undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of vancomycin and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after vancomycin administration.
Standard adult regimens span 750 mg/150mL Injection, Solution, 1 g/200mL Injection, Solution, 1.5 g/300mL Injection, Solution, 1.75 g/350mL Injection, Solution, 2 g/400mL Injection, Solution. Prescribers screen specifically against 4 contraindications tyzavan is contraindicated in patients with known hypersensitivity to vancomycin.; hypersensitivity to vancomycin ( 4 ), while community micro-logs most frequently note diarrhea (10% of reports), nausea (8.4% of reports), headache (6.6% of reports).
Reconcile eGFR-adjusted medications before escalating Vancomycin in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Vancomycin maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS TYZAVAN is contraindicated in patients with known hypersensitivity to vancomycin.
- Hypersensitivity to vancomycin ( 4 )
Logged Side-Effect Incidence (12 Reports)
Vancomycin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vancomycin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
| Can This Approach Help? Inside the Latest Research on Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides This analysis provides further evidence of RBL real-world benefits and safety across subgroups, including those at high risk for rCDI. Journal of clinical gastroenterology • 2024-09-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38019088 ↗ |
| Can This Approach Help? Inside the Latest Research on Effectiveness and safety of oral vancomycin versus placebo in the prevention of Ethical approval has been obtained from the Ethic Committee for Research with medicinal products of the University Hospital '12 de Octubre' (AC069/18) and from the Spanish Medicines and Healthcare Product Regulatory Agency... BMJ open • 2023-09-13 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37709311 ↗ |
| Can This Approach Help? Inside the Latest Research on Does skin-applied Vancomycin Powder Use in Fracture Surgery Change Bacteriology Applied to the skin vancomycin powder decreases the likelihood of gram-positive infections consistent with the biologic activity of vancomycin. Journal of orthopaedic trauma • 2024-04-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38206761 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Ceftobiprole was well tolerated and, in this small phase 3 study, demonstrated similar efficacy to SoC cephalosporins in children patients with HAP or CAP requiring hospitalization. The Pediatric infectious disease journal • 2021-06-01 • Phase III Randomized Trial | N = 94 | 82/100 | PMID 33480665 ↗ |
Vancomycin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.3416/unit (~$10.25/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $22.25 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $54.51 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $25.59 / mo | View logs ↓ |
Vancomycin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vancomycin RxNorm Concept ID | 1807508 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3416 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $54.51 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $22.25 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 90.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vancomycin Patient Community, Cohort Filters & Dosage Logs
Deterministic Vancomycin reference combining NIH RxNorm (1807508), Medicaid NADAC ($0.3416/unit), and anonymous cohort outcomes (90% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vancomycin community threads and patient logs by age, biological sex, dosage, and treatment duration.